Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Japan Approves Symbicort Generics, Asthma Drug Stalwart Could Face Competition in June
The Ministry of Health, Labor and Welfare (MHLW) on February 15 gave the green light to a raft of new generic drugs ahead of the next generic reimbursement listing in June, including lower-cost copies of AstraZeneca’s asthma treatment Symbicort (budesonide…
To read the full story
Related Article
- 15% Share Eyed for Jointly Developed Symbicort Generics, Toa Set to Push Uptake with Support App
December 25, 2019
- 6 Drugs Face Generic Entries, 2 Firms to Roll Out Symbicort Copies: December Listing
December 12, 2019
- Nesp Biosame to Join NHI Price List, Launch Due by September; Symbicort Generics, Teribone AG Skip Listing
June 13, 2019
- Toa Confident in Ensuring Stable Supply of Symbicort Generic with Expertise in Dry Powder Inhaler Manufacturing
March 8, 2019
- Nihon Generic Taking Pass on June Listing of Symbicort Copies; 2 Partners Mum
February 27, 2019
- Asahi Kasei Pharma Sets Up New Firm for Teribone Authorized Generic
February 18, 2019
- Toa, Nipro, Nihon Generic Codeveloped Symbicort Copies, Launch Timing Unclear
February 18, 2019
REGULATORY
- Officer Replacement Orders a “Last Resort” under PMD Act: MHLW Official
September 18, 2026
- Japan Panel Sees No Scientific Objection to Capvaxive NIP Addition
September 18, 2026
- Tavneos Blue Letter Action “Too Slow,” MHLW Panel Member Says
September 18, 2026
- Takaichi Tasks Ueno with Charting Growth Strategy for Drug Innovation
September 18, 2026
- Japan HIV, AIDS Cases Rise in H1 after 2025 Lows
September 18, 2026
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…